BSD SCIENCE

Company Overview

Snapshot

Founded in January 2022 by Yochai Yakovson, BSD SCIENCE operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing an oral drug delivery system. In 2022, BSD SCIENCE completed a POC PK animal study, achieving promising results and submitting a U.S. Provisional Patent Application.

Business overview

BSD SCIENCE is a biotech company specializing in the development of a unique oral dosage form for the controlled release of lipophilic drugs. This platform aims to achieve a longer duration of effect, reduce adverse effects, and improve treatment compliance. The technology is applicable to lipophilic molecules used in the medical cannabis, pharmaceutical, and dietary supplement markets, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

When was BSD SCIENCE founded and by whom?

BSD SCIENCE was founded in January 2022 by Yochai Yakovson, who serves as the Founder & CEO.

Which markets does BSD SCIENCE's platform target?

The platform developed by BSD SCIENCE is suitable for lipophilic molecules utilized in the Medical Cannabis, Pharma industry, and Dietary Supplement markets.

What significant milestone did BSD SCIENCE achieve in 2022?

In 2022, BSD SCIENCE completed a POC PK animal study, which yielded promising results, and subsequently submitted a U.S. Provisional Patent Application.

What are BSD SCIENCE's future development plans?

Following the successful POC PK animal study, BSD SCIENCE plans to advance towards a human PK study.